natgillin/translations-raw huggingface dataset:
A compound according to claim 1 or 2 for use in preventing or treating disorders or diseases mediated by lymphocytes, for preventing or treating acute or chronic transplant rejection or T-cell mediated inflammatory or autoimmune diseases, for inhibiting or controlling deregulated angiogenesis, or for preventing or treating diseases mediated by a neo-angiogenesis process or associated with deregulated angiogenesis in a subject. 
Spoj prema zahtjevu 1 ili 2, ili kombinacija prema zahtjevu 4, naznačen/a time, da se upotrebljava u liječenju ili prevenciji akutnog ili kroničnog odbacivanja transplantata alografta ili ksenografta, ili upalnih ili autoimunih poremećaja. Farmaceutska kombinacija, naznačena time, da obuhvaća terapeutski učinkovitu količinu spoja prema zahtjevu 1, u kombinaciji s jednim ili više od sljedećih:
is selected from H, cyano, trifluoromethoxy, and trifluoromethyl; 
je odabran od sljedećih: H, cijano, trifluorometoksi i trifluorometil;
is selected from cyclobutyl, cyclohexyl, cyclopentyl, and cyclopropyl; and 
je odabran od sljedećih: ciklobutil, cikloheksil, ciklopentil i ciklopropil; i
is selected from H, cyano, and trifluoromethyl. 
je odabran od sljedećih: H, cijano i trifluorometil.
is selected from cyclobutyl, cyclohexyl, cyclopentyl, and cyclopropyl. 
je odabran od sljedećih: ciklobutil, cikloheksil, ciklopentil i ciklopropil.
A compound, salt, hydrate, solvate, or composition for use according to claim 38, in a method of treatment of an S1P1 receptor-associated disorder. 
Spoj, sol, hidrat, solvat ili sastav za uporabu prema zahtjevu 38, naznačen/a time, da se upotrebljava u postupaku liječenja poremećaja povezanog s receptorom S1P1.
A compound, salt, hydrate, solvate, or composition for use according to claim 39, wherein said S1P1 receptor associated disorder is: a disease or disorder mediated by lymphocytes, an autoimmune disease or disorder, an inflammatory disease or disorder, biliary cirrhosis, cancer, psoriasis, psoriatic arthritis, rheumatoid arthritis, Crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, inflammatory bowel disease, ulcerative colitis, type I diabetes, or acne. 
Spoj, sol, hidrat, solvat ili sastav za uporabu prema zahtjevu 39, naznačen/a time, da je navedeni poremećaj povezan s receptorom S1P1, sljedeći: bolest ili poremećaj posredovan/a putem limfocita, autoimuna bolest ili poremećaj, upalna bolest ili poremećaj, bilijarna ciroza, rak, psorijaza, psorijatički artritis, reumatoidni artritis, Chronova bolest, odbacivanje transplantata, multipla skleroza, sistemska lupus eritematoza, upalna bolest crijeva, ulcerativni kolitis, dijabetes tipa I, ili akne.
A compound, salt, hydrate, solvate, or composition for use according to claim 39, wherein said S1P1 receptor associated disorder is biliary cirrhosis. 
Spoj, sol, hidrat, solvat ili sastav za uporabu prema zahtjevu 39, naznačen/a time, da navedeni poremećaj povezan s receptorom S1P1 je bilijarna ciroza.
A compound, salt, hydrate, solvate, or composition for use according to claim 39, wherein said S1P1 receptor associated disorder is psoriasis. 
Spoj, sol, hidrat, solvat ili sastav za uporabu prema zahtjevu 39, naznačen/a time, da navedeni poremećaj povezan s receptorom S1P1 je psorijaza.
A compound, salt, hydrate, solvate, or composition for use according to claim 39, wherein said S1P1 receptor associated disorder is psoriatic arthritis. 
Spoj, sol, hidrat, solvat ili sastav za uporabu prema zahtjevu 39, naznačen/a time, da navedeni poremećaj povezan s receptorom S1P1 je psorijatički artritis.
A compound, salt, hydrate, solvate, or composition for use according to claim 39, wherein said S1P1 receptor associated disorder is rheumatoid arthritis. 
Spoj, sol, hidrat, solvat ili sastav za uporabu prema zahtjevu 39, naznačen/a time, da navedeni poremećaj povezan s receptorom S1P1 je reumatoidni artritis.
A compound, salt, hydrate, solvate, or composition for use according to claim 39, wherein said S1P1 receptor associated disorder is Crohn's disease. 
Spoj, sol, hidrat, solvat ili sastav za uporabu prema zahtjevu 39, naznačen/a time, da navedeni poremećaj povezan s receptorom S1P1 je Chronova bolest.
A compound, salt, hydrate, solvate, or composition for use according to claim 39, wherein said S1P1 receptor associated disorder is multiple sclerosis. 
Spoj, sol, hidrat, solvat ili sastav za uporabu prema zahtjevu 39, naznačen/a time, da navedeni poremećaj povezan s receptorom S1P1 je multipla skleroza.
A compound, salt, hydrate, solvate, or composition for use according to claim 39, wherein said S1P1 receptor associated disorder is inflammatory bowel disease. 
Spoj, sol, hidrat, solvat ili sastav za uporabu prema zahtjevu 39, naznačen/a time, da navedeni poremećaj povezan s receptorom S1P1 je upalna bolest crijeva.
A compound, salt, hydrate, solvate, or composition for use according to claim 39, wherein said S1P1 receptor associated disorder is ulcerative colitis. 
Spoj, sol, hidrat, solvat ili sastav za uporabu prema zahtjevu 39, naznačen/a time, da navedeni poremećaj povezan s receptorom S1P1 je ulcerativni kolitis.
A compound, salt, hydrate, solvate, or composition for use according to claim 39, wherein said S1P1 receptor associated disorder is a microbial infection or disease or a viral infection or disease. 
Spoj, sol, hidrat, solvat ili sastav za uporabu prema zahtjevu 39, naznačen/a time, da navedeni poremećaj povezan s receptorom S1P1 je mikrobna infekcija ili bolest, ili je virusna infekcija ili bolest.
Use of a compound according to any one of claims 1 to 31, a salt according to claim 32 or 33, a hydrate according to claim 34, a solvate according to claim 35, or a pharmaceutical composition according to claim 36 in the manufacture of a medicament for the treatment of an S1P1 receptor-associated disorder. 
Uporaba spoja prema bilo kojem od zahtjeva 1 do 31, soli prema zahtjevu 32 ili 33, hidrata prema zahtjevu 34, solvata prema zahtjevu 35, ili farmaceutskog sastava prema zahtjevu 36, naznačena time, da je za proizvodnju lijeka za liječenje poremećaja povezanog s receptorom S1P1.
Use according to claim 50, wherein said S1P1 receptor associated disorder is: a disease or disorder mediated by lymphocytes, an autoimmune disease or disorder, an inflammatory disease or disorder, biliary cirrhosis, cancer, psoriasis, psoriatic arthritis, rheumatoid arthritis, Crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, inflammatory bowel disease, ulcerative colitis, type I diabetes, or acne. 
Uporaba prema zahtjevu 50, naznačena time, da je navedeni poremećaj povezan s receptorom S1P1, sljedeći: bolest ili poremećaj posredovan/a putem limfocita, autoimuna bolest ili poremećaj, upalna bolest ili poremećaj, bilijarna ciroza, rak, psorijaza, psorijatički artritis, reumatoidni artritis, Chronova bolest, odbacivanje transplantata, multipla skleroza, sistemska lupus eritematoza, upalna bolest crijeva, ulcerativni kolitis, dijabetes tipa I, ili akne.
Use according to claim 50, wherein said S1P1 receptor associated disorder is biliary cirrhosis. 
Uporaba prema zahtjevu 50, naznačena time, da navedeni poremećaj povezan s receptorom S1P1 je bilijarna ciroza.
Use according to claim 50, wherein said S1P1 receptor associated disorder is psoriasis. 
Uporaba prema zahtjevu 50, naznačena time, da navedeni poremećaj povezan s receptorom S1P1 je psorijaza.
Use according to claim 50, wherein said S1P1 receptor associated disorder is psoriatic arthritis. 
Uporaba prema zahtjevu 50, naznačena time, da navedeni poremećaj povezan s receptorom S1P1 je psorijatički artritis.
Use according to claim 50, wherein said S1P1 receptor associated disorder is rheumatoid arthritis. 
Uporaba prema zahtjevu 50, naznačena time, da navedeni poremećaj povezan s receptorom S1P1 je reumatoidni artritis.
Use according to claim 50, wherein said S1P1 receptor associated disorder is Crohn's disease. 
Uporaba prema zahtjevu 50, naznačena time, da navedeni poremećaj povezan s receptorom S1P1 je Chronova bolest.
Use according to claim 50, wherein said S1P1 receptor associated disorder is multiple sclerosis. 
Uporaba prema zahtjevu 50, naznačena time, da navedeni poremećaj povezan s receptorom S1P1 je multipla skleroza.
Use according to claim 50, wherein said S1P1 receptor associated disorder is ulcerative colitis. 
Uporaba prema zahtjevu 50, naznačena time, da navedeni poremećaj povezan s receptorom S1P1 je ulcerativni kolitis.
Use according to claim 50, wherein said S1P1 receptor associated disorder is a microbial infection or disease or a viral infection or disease. 
Uporaba prema zahtjevu 50, naznačena time, da navedeni poremećaj povezan s receptorom S1P1 je mikrobna infekcija ili bolest, ili je virusna infekcija ili bolest.
Ring A is an optionally substituted benzene ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, or an optionally substituted unsaturated fused heterobicyclic ring wherein Y is linked to the heterocyclic ring of the fused heterobicyclic ring; or 
Prsten A je opcionalno supstituirani benzenov prsten, i Prsten B je opcionalno supstituirani nezasićeni monociklički heterociklički prsten, ili opcionalno supstituirani nezasićeni srašteni heterobiciklički prsten pri čemu je Y povezan na heterociklički prsten sraštenog heterobicikličkog prstena; ili
A process as in Claim 1 or Claim 2, wherein the zinc salt and the organo-lithium reagent are pre-mixed for a period of about 1 to about 2 hours. 
Proces prema patentnom zahtjevu 1 ili patentnom zahtjevu 2, naznačen time da su cinkova sol, i organo-litijev reagens prethodno miješani tijekom perioda od oko 1 do oko 2 sata.
Ring A is selected from the group consisting of 4-methylphenyl and 4-chlorophenyl; 
Prsten A je izabran iz grupe koja se sastoji od 4-metilfenila i 4-klorofenila;
A fibre moulded package (1) for accommodating foodstuffs such as eggs which package comprises; 
Pakiranje oblikovano vlaknima (1) za pohranu namirnica poput jaja koje pakiranje sadrži;
a cover part (4) coupled with the base part and hingeable around an hinge (19) relative to the base part between a closed position and an open position, wherein the cover part comprises a a window section (5) for providing a view to the interior of the package from the outside, 
pokrovni dio (4) spojen s osnovnim dijelom i pomičan oko šarke (19) u odnosu na osnovni dio između zatvorenog položaja i otvorenog položaja, pri čemu pokrovni dio obuhvaća prozorski dio (5) za omogućavanje uvida u unutrašnjost pakiranja,
locking members (6, 7, 22) arranged opposite the hinge for holding the cover part in its closed position, characterized in, that the cover part comprises a cover part top surface (8) which is generally flat for enabling printing onto the cover part top surface, and wherein the window section comprises a window plane (9) which extends from about the centre of the cover part towards the locking members at a slight angle (a) between 10° - 35° with respect to the cover part top surface for providing resistant strength to the cover part. 
sredstva za zatvaranje (6, 7, 22) smještena nasuprot šarke za držanje dijela za zatvaranje u zatvorenom položaju, naznačeno time, što pokrovni dio sadrži gornju površinu pokrovnog dijela (8) koja je općenito ravna za omogućavanje printanja na gornju površinu pokrovnog dijela, i pri čemu prozorski dio obuhvaća ravninu prozora (9) koja se pruža od otprilike sredine pokrovnog dijela prema članovima za zaključavanje pod blagim kutem (a) između 10° - 35° u odnosu na pokrov gornjeg dijela za pružanje otpora pokrovnom dijelu.
A fibre moulded package (1) according to claim 1, wherein the slight angle (a) is about 30°. 
Pakiranje oblikovano vlaknima (1) sukladno zahtjevu 1, pri čemu je blagi kut (a) oko 30°.
A fibre moulded package (1) according to a preceding claim, wherein the window section comprises a single window plane (9). 
Pakiranje oblikovano vlaknima (1) sukladno prethodnom zahtjevu, pri čemu dio prozora obuhvaća jednu ravninu prozora (9).
A fibre moulded package (1) according to claim 5, wherein the window section comprise a number of respective window frame members (10) which delimit a number of respective window openings (12). 
Pakiranje oblikovano vlaknima (1) sukladno zahtjevu 5, pri čemu dio prozora obuhvaća više odnosnih dijelova okvira (10) koji određuju broj odnosnih otvora prozora (12).
A fibre moulded package (1) according to claim 6, wherein each of the number of window frame members (10) has a respective stop surface (11). 
Pakiranje oblikovano vlaknima (1) sukladno zahtjevu 6, pri čemu svaki od više članova okvira prozora (10) ima odnosnu zaustavnu površinu (11).
A fibre moulded package (1) according to any of claims -5-7, wherein the window frame member comprises a rim (13) adjacent the stop surface for facilitating secure engaging of the stop surface and the base part when the cover part is in its closed position. 
Pakiranje oblikovano vlaknima sukladno bilo kojem od zahtjeva -5-7, pri čemu članak okvira prozora sadrži rub (13) uz zaustavnu površinu za olakšavanje sigurnog rada zaustavne površine i osnovni dio kada je pokrovni dio u zatvorenom položaju.
A fibre moulded package (1) according to any of claims 5-8, wherein the window frame member comprises two adjacent rims (13, 14) which mutually enclose an angle. 
Pakiranje oblikovano vlaknima (1) sukladno bilo kojem od zahtjeva 5-8, pri čemu članak okvira prozora sadrži dva susjedna ruba (13, 14) koji međusobno zatvaraju kut.
A fibre moulded package (1) according to any of claims 5 - 9, wherein all of the number of window openings extend in the window plane. 
Pakiranje oblikovano vlaknima (1) sukladno bilo kojem od zahtjeva 5 - 9, pri čemu se svi od više otvora prozora pružaju u ravnini prozora.
A fibre moulded package (1) according to a preceding claim, wherein the cover part is provided with a circumferential substantially planar side wall (15) for enabling printing onto the side wall, which side wall extends from the cover part top surface. 
Pakiranje oblikovano vlaknima (1) sukladno prethodnom zahtjevu, pri čemu je pokrovni dio opremljen cirkumferencijalnim supstancijalnim planarnim bočnim zidom (15) za omogućavanje ispisivanja na zid, koji se bočni zid pruža od gornje površine pokrovnog dijela.
A fibre moulded package (1) according to a preceding claim, wherein the window section is arranged with the cover part top surface at a position such that the number of stop surfaces are proximate the locking members. 
Pakiranje oblikovano vlaknima (1) sukladno prethodnom zahtjevu, pri čemu je prozorski dio organiziran s gornjom površinom pokrovnog dijela u položaju na način da se više površina za zaustavljanje nalazi u blizini dijelova za zatvaranje.
A fibre moulded package (1) according to a preceding claim, wherein a corner of the cover part 4, preferably all four corners of the cover part 4, comprises a bulge 27 and a curved sections 28, which bulge couples two adjoining sidewalls at the corner, and which curved section 28 is provided between the cover part top surface 8 and the bulge 27, and wherein the curved section 28 bridges the entire corner between the two adjoining side walls. 
Pakiranje oblikovano vlaknima (1) sukladno prethodnim zahtjevima, pri čemu kut pokrovnog dijela 4, poželjno sva četiri kuta pokrovnog dijela 4, obuhvaća izbočenje 27 i zavojite dijelove 28, koja izbočina spaja dva susjedna bočna zida u kutu, i koje je izbočenje 28 pruženo između pokrovnog dijela gornje površine 8 i izbočine 27, i pri čemu zavojiti dio 28 premošćuje čitavi kut između dva susjedna bočna zida.
The method of claim 4, wherein the reversible blocking is performed by a chemical species attached to a 3' end of the unextended amplification oligonucleotides. 
Metoda iz patentnog zahtjeva 5, pri čemu je reverzibilno blokiranje pomoću kemijskih vrsta pričvršćenih na 3' kraju oligonukleotida za umnožavanje.
A pharmaceutical kit for the in situ formation of a biodegradable implant in a body comprising the composition of any one of claims 1-14, wherein the drug and the biocompatible polymer are contained in a first container, and the water-miscible solvent is contained in a second, separate container. 
Farmaceutski komplet za in situ formiranje biorazgradivog implantata u tijelu koji sadrži sastav iz bilo kojeg od patentnih zahtjeva 1 do 12, naznačen time što su lijek i biorazgradivi polimer sadržani u prvom spremniku, a otapalo se nalazi u drugom, zasebnom spremniku.
A mobile device comprising: a receive antenna (1742) and a transmit antenna (1752); 
Mobilni uređaj koji se sastoji od: prijemne antene (1742) i odašiljačke antene (1752);
characterized in that the mobile device comprises an active transmit circuit (2130) coupled between the smartcard controller (330) and the transmit antenna (1752) that in operation forms a signal that mimics the at least one of the frequency sideband and wherein the signal drives the transmit antenna (1752). 
naznačeni time da se navedeni mobilni uređaj sastoji od aktivnog odašiljačkog sklopa (2130) spojenog između kontrolera pametne kartice (330) i odašiljačke antene (1752) koja pri radu stvara signal koji oponaša najmanje jedan frekvencijski pojas, pri čemu signal pokreće odašiljačku antenu (1752).
The mobile device of claim 1 wherein the transmit antenna and receive antenna are one antenna (1542). 
Mobilni uređaj iz zahtjeva 1, naznačen time da su odašiljačka i prijemna antena jedna antena (1542).
The mobile device of claim 1 or 2 wherein the smartcard controller includes a pad (2410) coupled to the active transmit circuit (2130) to provide digital data to the active transmit circuit (2130). 
Mobilni uređaj iz zahtjeva 1 i 2, naznačen time da kontroler pametne kartice uključuje podlogu (2410) spojenu na aktivni odašiljački sklop (2130) kako bi isti primio digitalne podatke.
n is 0, 1 or 2; if n is 2 then R4 may be the same or different; 
n je 0, 1 ili 2; ako n je 2, tada R4 može biti isti ili drugačiji;
or pharmaceutically active acid addition salts thereof, with the exception of 
ili njegove farmaceutski djelotvorne kiselinske adicijske soli, s izuzetkom od sljedećih:
A compound of formula I according to claim 1, wherein hetaryl I is and hetaryl II is a bicyclic ring system containing 1 to 4 heteroatoms as defined in claim 1. 
Spoj formule I prema zahtjevu 1, naznačen time, da hetaril I je: [image] i hetaril II je biciklički sustav prstena, koji ima od 1 do 4 heteroatoma kao što je definirano u zahtjevu 1.
A compound of formula I according to claim 1, wherein hetaryl 1 is and hetaryl II is a bicyclic ring system containing 1 to 4 heteroatoms as defined in claim 1. 
Spoj formule I prema zahtjevu 1, naznačen time, da hetaril I je: [image] i hetaril II je biciklički sustav prstena, koji ima od 1 do 4 heteroatoma kao što je definirano u zahtjevu 1.
reacting a compound of formula with a compound of formula to a compound of formula wherein X is halogen and the further groups have the meaning as described in claim 1 and, if desired, converting the compounds obtained into pharmaceutically acceptable acid addition salts; or 
[image] u kojoj X je halogen, a sljedeće skupine imaju značenje kao što je opisano u zahtjevu 1, te ako se želi, pretvaranje dobivenih spojeva u farmaceutski prihvatljive kiselinske adicijske soli; ili reakcija spoja sljedeće formule:
reacting a compound of formula with a compound of formula to a compound of formula wherein the groups have the meaning as described above and R3 is hydrogen, and, if desired converting the compounds obtained into pharmaceutically acceptable acid addition salts. 
[image] sa spojem sljedeće formule: [image] u spoj sljedeće formule: [image] u kojoj skupine imaju značenje kao što je gore opisano i R3 je vodik, te ako se želi, pretvaranje dobivenih spojeva u farmaceutski prihvatljive kiselinske adicijske soli.
A medicament according to claim 15 for the treatment of Alzheimer's disease, cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi-infarct dementia, dementia pugilistica or Down syndrome. 
Lijek prema zahtjevu 15, naznačen time, da se upotrebljava u liječenju Alzheimerove bolesti, cerebralne amiloidne angiopatije, nasljedne cerebralne hemoragije s amiloidozom, nizozemskog tipa HCHWA-D, višestruki infarkti-demencije, demencije pugilistika ili Downovog sindroma.
The use of a compound in any one of claims 1 - 13 for the manufacture of medicaments for the treatment of Alzheimer's disease, cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi-infarct dementia, dementia pugilistica or Down syndrome. 
Uporaba spoja prema bilo kojem od zahtjeva 1 do 13, naznačena time, da je za proizvodnju lijekova za liječenje Alzheimerove bolesti, cerebralne amiloidne angiopatije, nasljedne cerebralne hemoragije s amiloidozom, nizozemskog tipa HCHWA-D, višestruki infarkti-demencije, demencije pugilistika ili Downovog sindroma.
A compound according to any one of claims 1 - 13 for the treatment of Alzheimer's disease, cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi-infarct dementia, dementia pugilistica or Down syndrome. 
Spoj prema bilo kojem od zahtjeva 1 do 13, naznačen time, da se upotrebljava za liječenje Alzheimerove bolesti, cerebralne amiloidne angiopatije, nasljedne cerebralne hemoragije s amiloidozom, nizozemskog tipa HCHWA-D, višestruki infarkti-demencije, demencije pugilistika ili Downovog sindroma.
a generally disk-shaped floatable cage tapering towards the periphery of the cage in a peripheral region thereof; and a water-repellent strip-shaped oil absorbent accommodated in the cage, wherein the cage further comprises at least one connector element configured for joining plural ones of the modular devices together, to form an articulate oil absorber in which the individual cages are oriented in parallel to one another. 
Plutajući modularni uređaj za apsorpciju ulja s površine, a koji je sastavljen od plutajućeg kaveza u obliku diska sa zašiljenjem prema periferiji kaveza; i apsorbera ulja koji odbija vodu, u obliku trake, a koji je smješten u kavezu, pri čemu pri čemu je kavez dalje sastavljen od barem jednog priključnog elementa koji je namijenjen za spajanje više modularnih uređaja kako bi isti formirali skupni apsorber nafte unutar kojeg su pojedinačni kavezi paralelni jedni s drugim.")
65), wherein "X1", "X2", "X3" or "X4" represents any amino acid residue, and the amino acid residue "D" corresponds to Kabat position 95 of CDR-H3 of murine monoclonal antibody A5B7 and the amino acid residues "FYFDY" correspond to Kabat positions 100, 100a, 100b, 101, and 102, respectively, of CDR-H3 of murine monoclonal antibody A5B7. 
65), gdje "X1", "X2", "X3" ili "X4" predstavlja bilo koji aminokiselinski ostatak, aminokiselinski ostatak "D" odgovara Kabatovom položaju 95 u CDR-H3 mišjeg monoklonskog protutijela A5B7, a aminokiselina ostaci "FYFDY" odgovaraju Kabatovim položajima 100, 100a, 100b, 101 odnosno 102 u CDR-H3 mišjeg monoklonskog protutijela A5B7.
The pharmaceutical composition of any of claims 1 to 6, wherein the amino acid sequence of the VH region of the second binding domain specific for human CEA is SEQ ID NO. 
Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačen time što je aminokiselinski slijed VH područja u drugoj vežućoj domeni specifičnoj za ljudski CEA SEQ ID NO.
The pharmaceutical composition of any of claims 1 to 7, wherein the amino acid sequence of the VL region of the second binding domain specific for human CEA is SEQ ID NO. 
Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 7, naznačen time što je aminokiselinski slijed VL područja u drugoj vežućoj domeni specifičnoj za ljudski CEA SEQ ID NO.
The pharmaceutical composition of any one of claims 1 to 8, wherein the V regions of the second binding domain specific for CEA are selected from the group consisting of: 
Farmaceutski pripravak u skladu s bilo koji od patentnih zahtjeva 1 do 8, naznačen time što se V područja u drugoj vežućoj domeni specifičnoj za CEA bira iz skupine koju čine: